Joël Jean-Mairet, Ph.D.
Joël Jean-Miret is managing partner and co-founder of Ysios Capital. Previously, he co-founded Glycart Biotechnology AG in 2001 and was its CEO until the company was successfully sold to F. Hoffmann La-Roche four years later. He holds an MS in Biotechnology and a Ph.D. from the Swiss Federal Institute of Technology (ETH) in Zurich.
Joël is currently on the boards of directors of AM-Pharma B.V., Medlumics S.A., Sanifit S.L., Dermalumics S.L. and Chairman of Inbiomotion S.L. He has been Chairman of the board of Cellerix (now Tigenix NYSE Euronext TIG) and board observer at Boston-based Biovex, Inc. (now Amgen). Joël has earned numerous awards, including the Wall Street Journal’s Europe Innovation Award in 2001.